A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06647134
Status
Recruiting
Apply to this trial

Conditions

  • Arthritis
  • Immune Checkpoint Inhibitors
  • Polymyalgia Rheumatica

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.

Key Dates

Start date
Sep 11, 2024
Status verified
Apr 2026
Primary completion
Mar 31, 2028
Completion
Mar 31, 2028

Study Design

Enrollment
20 participants (estimated)

Primary Outcome Measure

Safety and Adverse Events (AEs). [ Time Frame: Through study completion; an average of 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Y. Jeff Li, MD
[email protected]
713-409-1565
Y. Jeff Li, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies